Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CILAZAPRIL

6 general benefit · 2 not a benefit

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Mylan-Cilazapril · DIN 02283778 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Cilazapril · DIN 02283778 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-09-06 Health Canada: Marketed since 2010-01-07 · brand MYLAN-CILAZAPRIL · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 1 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Cilazapril: Formulary list price $0.3426/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3426 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76935 · Verify on the e-Formulary ↗ (DIN 02283778)

Source record
DIN 02283778: Mylan-Cilazapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800189; group id 318; item number 0705; lccId None; manufacturer id MYL Source form: Tab; strength: 1mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3426; ministry $0.3426 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02283778 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76935
Interchangeable products
Inhibace · DIN 01911465 · not recorded
Shortage status: resolved shortage (ended 2026-04-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02283778
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Cilazapril · DIN 02291142 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Cilazapril · DIN 02291142 Manufacturer: Apotex Inc.; listing date 2007-03-09 Daily cost (source): $0.4295 Health Canada: Marketed since 2007-02-01 · brand APO-CILAZAPRIL · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 2.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Cilazapril: Formulary list price $0.4295/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4295 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77652 · Verify on the e-Formulary ↗ (DIN 02291142)

Source record
DIN 02291142: Apo-Cilazapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800190; group id 318; item number 0706; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4295; ministry $0.4295 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291142 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77652
Interchangeable products
Inhibace · DIN 01911473 · not recorded Mylan-Cilazapril · DIN 02283786 · $0.4295
Shortage status: resolved shortage (ended 2020-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291142
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Cilazapril · DIN 02283786 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Cilazapril · DIN 02283786 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-09-06 Daily cost (source): $0.4295 Health Canada: Marketed since 2010-01-05 · brand MYLAN-CILAZAPRIL · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 2.5 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Cilazapril: Formulary list price $0.4295/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4295 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76936 · Verify on the e-Formulary ↗ (DIN 02283786)

Source record
DIN 02283786: Mylan-Cilazapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800190; group id 318; item number 0706; lccId None; manufacturer id MYL Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4295; ministry $0.4295 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02283786 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76936
Interchangeable products
Apo-Cilazapril · DIN 02291142 · $0.4295 Inhibace · DIN 01911473 · not recorded
Shortage status: resolved shortage (ended 2026-04-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02283786
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Cilazapril · DIN 02291150 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Cilazapril · DIN 02291150 Manufacturer: Apotex Inc.; listing date 2007-03-09 Daily cost (source): $0.4989 Health Canada: Marketed since 2007-02-01 · brand APO-CILAZAPRIL · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Cilazapril: Formulary list price $0.4989/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4989 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77653 · Verify on the e-Formulary ↗ (DIN 02291150)

Source record
DIN 02291150: Apo-Cilazapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800191; group id 318; item number 0707; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4989; ministry $0.4989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291150 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77653
Interchangeable products
Inhibace · DIN 01911481 · $0.4989 Mylan-Cilazapril · DIN 02283794 · $0.4989
Shortage status: resolved shortage (ended 2022-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291150
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Inhibace · DIN 01911481 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Inhibace · DIN 01911481 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 1996-10-01 Daily cost (source): $1.1698 Health Canada: Marketed since 2019-08-19 · brand INHIBACE · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 5 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4989 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13834 · Verify on the e-Formulary ↗ (DIN 01911481)

Source record
DIN 01911481: Inhibace Raw flags: chronicUseMed=Y, sec3=Y Item: 240800191; group id 318; item number 0707; lccId None; manufacturer id CHE Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.1698; ministry $0.4989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01911481 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13834
Interchangeable products
Apo-Cilazapril · DIN 02291150 · $0.4989 Mylan-Cilazapril · DIN 02283794 · $0.4989
Shortage status: resolved shortage (ended 2021-09-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911481
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Cilazapril · DIN 02283794 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Cilazapril · DIN 02283794 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-09-06 Daily cost (source): $0.4989 Health Canada: Marketed since 2010-01-07 · brand MYLAN-CILAZAPRIL · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 5.0 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Cilazapril: Formulary list price $0.4989/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4989 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76937 · Verify on the e-Formulary ↗ (DIN 02283794)

Source record
DIN 02283794: Mylan-Cilazapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800191; group id 318; item number 0707; lccId None; manufacturer id MYL Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4989; ministry $0.4989 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02283794 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76937
Interchangeable products
Apo-Cilazapril · DIN 02291150 · $0.4989 Inhibace · DIN 01911481 · $0.4989
Shortage status: resolved shortage (ended 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02283794
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Inhibace · DIN 01911473 · 2.5mg · tablet

Listed, not a benefitDormant since 2021-06-16 · checked 2026-09-02 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Inhibace · DIN 01911473 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Daily cost (source): $0.4295 Health Canada: Dormant since 2021-06-16 · brand INHIBACE · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 2.5 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Inhibace: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13835 · Verify on the e-Formulary ↗ (DIN 01911473)

Source record
DIN 01911473: Inhibace Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800190; group id 318; item number 0706; lccId None; manufacturer id HLR Source form: Tab; strength: 2.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01911473 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13835
Interchangeable products
Apo-Cilazapril · DIN 02291142 · $0.4295 Mylan-Cilazapril · DIN 02283786 · $0.4295
Shortage status: active shortage (reported 2018-11-26, last updated 2019-02-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911473
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-06-16 — choose a marketed DIN from the same-category list.

Inhibace · DIN 01911465 · 1mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-21 — choose a marketed DIN from the same-category list.Discontinued 2010-07-21 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-21 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-07-21 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Inhibace · DIN 01911465 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2010-07-21 · brand INHIBACE TAB 1MG · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL 1 MG · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Inhibace: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13836 · Verify on the e-Formulary ↗ (DIN 01911465)

Source record
DIN 01911465: Inhibace Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800189; group id 318; item number 0705; lccId None; manufacturer id HLR Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01911465 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13836
Interchangeable products
Mylan-Cilazapril · DIN 02283778 · $0.3426
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911465
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-07-21 — choose a marketed DIN from the same-category list.

CILAZAPRIL & HYDROCHLOROTHIAZIDE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Apo-Cilazapril/HCTZ · DIN 02284987 · 5mg/12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Cilazapril/HCTZ · DIN 02284987 Manufacturer: Apotex Inc.; listing date 2007-01-02 Health Canada: Marketed since 2006-08-23 · brand APO-CILAZAPRIL/HCTZ · ATC C09BA08 CILAZAPRIL AND DIURETICS, C09BA08 CILAZAPRIL AND DIURETICS · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 5 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Cilazapril/HCTZ: Formulary list price $0.6306/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6306 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77051 · Verify on the e-Formulary ↗ (DIN 02284987)

Source record
DIN 02284987: Apo-Cilazapril/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800236; group id 319; item number 0708; lccId None; manufacturer id APX Source form: Tab; strength: 5mg/12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6306; ministry $0.6306 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284987 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77051
Interchangeable products
Inhibace Plus · DIN 02181479 · $0.6306
Shortage status: resolved shortage (ended 2023-11-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284987
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Inhibace Plus · DIN 02181479 · 5mg/12.5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Inhibace Plus · DIN 02181479 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2000-01-17 Health Canada: Marketed since 2018-12-12 · brand INHIBACE PLUS · ATC C09BA08 CILAZAPRIL AND DIURETICS, C09BA08 CILAZAPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 5 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.6306 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44252 · Verify on the e-Formulary ↗ (DIN 02181479)

Source record
DIN 02181479: Inhibace Plus Raw flags: chronicUseMed=Y, sec3=Y Item: 240800236; group id 319; item number 0708; lccId None; manufacturer id CHE Source form: Tab; strength: 5mg/12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.1694; ministry $0.6306 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02181479 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44252
Interchangeable products
Apo-Cilazapril/HCTZ · DIN 02284987 · $0.6306
Shortage status: resolved shortage (ended 2024-10-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02181479
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph FELODIPINE · General benefit (10), Listed, not a benefit (2) 1 INDICATIONS PLENDIL (felodipine) is indicated for: • the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082730.PDF; date 2025-12-09; DIN 00851779; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE INHIBACE (cilazapril) is indicated in the treatment of mild to moderate essential hypertension. INHIBACE may be used alone or in combination with thiazide-type diuretics. INHIBACE is also indicated in the treatment of congestive heart failure as an adjunctive therapy with digitalis and/or diuretics. In using INHIBACE consideration should be given to the risk of angioedema (see WARNINGS AND PRECAUTIONS). Hypertension INHIBACE should normally be used in those patients in whom treatment with a diuretic or a beta-blocker was found ineffective or has been associated with unacceptable adverse effects. INHIBACE can also be tried as an initial agent in those patients in whom use of diuretics and/or beta-blockers is contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects. The safety and efficacy of INHIBACE in renovascular hypertension has not been established and therefore, its use in this condition is not recommended. Page 3 of 51 The safety and efficacy of concomitant use of INHIBACE with antihyperte… https://pdf.hres.ca/dpd_pm/00056636.PDF PM date: June 2, 2020 Source product: INHIBACE; DIN 01911481; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. INHIBACE PLUS is not indicated for initial therapy. Patients should be titrated on the individual drugs. The safety and efficacy of INHIBACE PLUS in congestive heart failure and renovascular hypertension have not been established and therefore, its use in these conditions is not recommended. The safety and efficacy of concomitant use of cilazapril with antihypertensive agents other than thiazide diuretics have not been established. 1.1 Pediatrics Pediatrics (birth - <18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of INHIBACE PLUS in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for this age group. 1.2 Geriatrics Although clinical experience has not identified differences in response between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out (see 7 WARNINGS AND PRECAUTIO… https://pdf.hres.ca/dpd_pm/00066994.PDF PM date: September 07, 1995 Source product: INHIBACE PLUS; DIN 02181479; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Inhibace · DIN 01911473 Shortage status: active shortage (reported 2018-11-26, last updated 2019-02-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911473

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Inhibace: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026